- Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
- Aldeyra Therapeutics to Host Investor Roundtable Q&A
- Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
More ▼
Key statistics
On Wednesday, Aldeyra Therapeutics Inc (ALDX:NAQ) closed at 3.20, 125.35% above the 52 week low of 1.42 set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.22 |
---|---|
High | 3.30 |
Low | 3.15 |
Bid | 3.15 |
Offer | 3.22 |
Previous close | 3.25 |
Average volume | 531.51k |
---|---|
Shares outstanding | 59.41m |
Free float | 48.66m |
P/E (TTM) | -- |
Market cap | 193.10m USD |
EPS (TTM) | -0.5080 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼